MedTrace Logo

C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine Effectiveness in Metastatic Colon Cancer

NCT03852290 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2020-03-26

No results posted yet for this study

Summary

Fluoropyrimidines are the backbone of chemotherapy regimes used to treat metastatic colorectal cancer (CRC). These drugs act in different pathways of folate metabolism altering DNA synthesis mainly by inhibition of the tymidylate synthase. For this reaction the 5,10-methylenetetrahydrofolate acts as cofactor. It has been demonstrated that A1298C and C677T polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene result in reduced enzyme activity that leads to reduced availability of this important cofactor. Hence, we hypothesized that the presence of these polymorphisms are related to the efficacy and toxicity of fluoropyrimidines in patients with CRC.

Conditions

  • Colon Cancer
  • MTHFR Gene Mutation
  • Chemotherapeutic Toxicity
  • Chemotherapy Effect

Sponsors & Collaborators

  • Universitat Autonoma de Barcelona

    collaborator OTHER

  • Universidad de Costa Rica

    lead OTHER

Principal Investigators

  • Allan Ramos-Esquivel, Mic · Universidad de Costa Rica

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-16
Primary Completion
2021-10-01
Completion
2021-10-01

Countries

  • Costa Rica

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03852290 on ClinicalTrials.gov